methylprednisolone has been researched along with Severe Combined Immunodeficiency in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Atkinson, A; Grunebaum, E; Kavadas, FD; Roifman, CM; Somech, R | 1 |
| Grunebaum, E; Nahum, A; Reid, B; Roifman, CM | 1 |
| Chelstrom, LM; Ek, O; Gaynon, P; Myers, DE; Uckun, FM; Zeren, T | 1 |
3 other study(ies) available for methylprednisolone and Severe Combined Immunodeficiency
| Article | Year |
|---|---|
High-dose methylprednisolone is effective in the management of acute graft-versus-host disease in severe combined immune deficiency.
Topics: Acute Disease; Anti-Inflammatory Agents; Bone Marrow Transplantation; Disease-Free Survival; Female; Graft vs Host Disease; Humans; Infant; Infant, Newborn; Male; Methylprednisolone; Retrospective Studies; Severe Combined Immunodeficiency | 2008 |
Matched unrelated bone marrow transplant for Omenn syndrome.
Topics: Anti-Inflammatory Agents; Biomarkers; Bone Marrow Cells; Bone Marrow Transplantation; Chimerism; Female; Graft vs Host Disease; Histocompatibility; Humans; Immunoglobulins; Infant; Living Donors; Lymphocyte Count; Male; Methylprednisolone; Prospective Studies; Severe Combined Immunodeficiency; Treatment Outcome | 2009 |
Treatment of human B-cell precursor leukemia in SCID mice by using a combination of the anti-CD19 immunotoxin B43-PAP with the standard chemotherapeutic drugs vincristine, methylprednisolone, and L-asparaginase.
Topics: Animals; Antigens, CD19; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Burkitt Lymphoma; Humans; Immunotoxins; Methylprednisolone; Mice; Mice, SCID; N-Glycosyl Hydrolases; Plant Proteins; Protein Synthesis Inhibitors; Ribosome Inactivating Proteins, Type 1; Severe Combined Immunodeficiency; Vincristine | 1998 |